explore -WSS

explore

author：Wikipedia 2025-10-02 05:38:49 - browse：698

The biotech company Acelyrin, which raised more than $500 million in an IPO this year, ran into its first major setback Monday as its investigational anti-inflammatory drug missed the primary goal in a pivotal clinical trial.

Acelyrin’s medicine, a subcutaneous treatment called izokibep, is meant to clear up lesions for patients with the common skin disease hidradenitis suppurativa, or HS, an inflammatory disorder that leads to abscesses and scars. But after 16 weeks of treatment, patients who received izokibep did not show significant improvements compared to those taking a placebo, failing the study’s primary endpoint.

Acelyrin’s share price fell more than 60% in after-hours trading Monday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Poland's lawmakers approve a divisive law on Russian influence

leisure time

WSS

Campaign finance charge dropped from case against Sam Bankman

Sea level rise could wash away turtle breeding grounds around the world, researchers say

Novo pauses ads for weight loss drug Wegovy amid demand

A public health expert passes on football's full body collisions for youths

Tennessee law changes starting July 1 will restrict trans health care and fund more school safety

Doctors in states that ban abortion can still help patients

focus

explore

leisure time

Apple is now the first public company to be valued at $3 trillion

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Guidelines to prevent youth baseball injuries need more muscle

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Malaria cases in Florida and Texas: Here’s what you need to know

Young Chinese opt out of the rat race and pressures at home to pursue global nomad lifestyle

BioMarin wins approval for gene therapy to treat hemophilia A

Science's Marcia McNutt, trailblazer for women, encounters sexism scandal

Hollywood unions extend contract negotiations for actors

Bispecific antibodies are next new thing in cancer immunotherapy

explore

China demands US invite Hong Kong leader to economic meeting, adding to strains over crackdown

American TikTok star stuck in Dubai for months following rental car altercation

Judge orders hearing on Trump's motion to disqualify Fulton County DA

Novo: Oral version of Ozempic leads to 15% weight loss

Europe is fastest

FDA approves first new drug developed for postpartum depression

leisure time

focus

leisure time

explore